A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.
about
Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancerMinimally invasive surgery in gastrointestinal cancer: benefits, challenges, and solutions for underutilizationThe IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 montOptimizing adjuvant therapy and survivorship care of stage III colon cancer.Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised coComparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.'Trial Exegesis': Methods for Synthesizing Clinical and Patient Reported Outcome (PRO) Data in Trials to Inform Clinical Practice. A Systematic ReviewAdjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors.Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review.Impact on Loco-regional Control of Radiochemotherapeutic Sequence and Time to Initiation of Adjuvant Treatment in Stage II/III Rectal Cancer Patients Treated with Postoperative Concurrent RadiochemotherapyColorectal cancer treatmentThe impact of delayed chemotherapy on its completion and survival outcomes in stage II colon cancer patients.Exploiting novel molecular targets in gastrointestinal cancers.Effects of being uninsured or underinsured and living in extremely poor neighborhoods on colon cancer care and survival in California: historical cohort analysis, 1996-2011.Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.Targeting precision medicine toxicity: recent developments.Adequacy of the National Quality Forum's Colon Cancer Adjuvant Chemotherapy Quality Metric: Is 4 Months Soon Enough?Factors Affecting Use and Delay (≥8 Weeks) of Adjuvant Chemotherapy after Colorectal Cancer Surgery and the Impact of Chemotherapy-Use and Delay on Oncologic Outcomes.Chemotherapy use in stage III colon cancer: a National Cancer Database analysisOncologic outcomes of early adjuvant chemotherapy initiation in patients with stage III colon cancer.From Evidence-based Medicine to Personalized MedicineAssociation Between Time (Initiation and Length) and Oncological Outcomes for the Patients with Colon Cancer Treated with Adjuvant ChemotherapyHigh Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population.Single-institution experience of adjuvant 5-fluorouracil-based chemotherapy for stage III colon cancer.Progress and challenges in the adjuvant treatment of stage II and III colon cancers.Optimal time of initiating adjuvant chemotherapy after curative surgery in colorectal cancer patientsAdjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?Treatment in advanced colorectal cancer: what, when and how?Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 studyPostoperative complications in patients with rectal cancer are associated with delays in chemotherapy that lead to worse disease-free and overall survival.Accomplishments in 2008 in the adjuvant treatment of colon cancer.Adjuvant therapy for early colon cancer: current status.Adjuvant therapy in colon cancer.DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.Pharmacogenomics of fluorouracil -based chemotherapy toxicity.Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma.Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study.ESMO World Congress on Gastrointestinal Cancer And European Post-Chicago Melanoma/Skin Cancer Meeting.Improved survival with early adjuvant chemotherapy after colonic resection for stage III colonic cancer: A nationwide study.
P2860
Q24240635-EBE80110-BD98-4607-97D6-ADF14362E507Q27000105-E0FF7652-EDCB-4C62-BB3E-952A8750048EQ28681140-AD3096A4-7E8A-4780-8F51-01878CB21745Q30249616-89D98482-BE1B-4B6B-8714-6009059746D4Q30316930-85F7C5CB-E71F-440E-A78E-3E29CA7F4D9AQ30422095-40169A45-0459-472C-90F1-8929FD986EA5Q31125157-54BAEFF9-7BA4-42DB-A119-5A746C1C85C4Q33403424-D52E36B8-4B2B-422E-9171-F2FA0672CBB4Q33405177-5255862C-4BD9-4EC0-82A7-01125E1CDEC2Q33619231-EE3517F3-E351-4A30-86E3-8A48FBCD3FA7Q33947455-0A869682-D370-46A8-9431-375FBE4CC7A6Q34216044-A5C189B0-6999-4896-9C2B-945DD600D4E2Q34382777-20DD0D22-9C29-44EF-9536-654D726BA21EQ34455690-5B0F67FF-9897-4FB4-92CC-6CD24CF84B42Q34632080-366C2AED-EA6D-4D67-8AD2-DC5324C40023Q35019470-F4C1DF94-8F41-4E29-9C59-07D747E01F5BQ35133471-5394C2B9-237E-4420-9753-F68E5E845408Q35779217-62681AA3-C0B6-4F37-B2E1-B079A7D71FE0Q35978879-34AF30AF-44B6-4F63-8E9C-52C1C916119BQ36026010-D75C38F0-829B-406E-B791-E71AAE846009Q36403027-E4E4183A-9487-4427-B027-FCF2E9320FDEQ36643640-0C3754E0-802E-4B57-AEA8-BCD5D0EB0FB3Q36979735-A3F5425D-7E24-4CBF-A35C-ABCF612C3C6CQ37093977-93BF8489-531E-47E7-8E27-E4287828B3E7Q37134442-DC311B7B-AFD7-4A28-A2AF-E3CA4D21A3BEQ37157906-2CB1B9E6-B4F9-469E-AB4C-DB0A68EBDFDFQ37167151-06808123-B2D5-41F4-A396-6293DC1AF83EQ37225720-014E6A22-5662-4E23-9922-BAC16B7ABC09Q37446505-22766862-959C-4B33-9752-19601C705D4FQ37447997-70122A24-58EE-4128-81DF-A81F5D876AABQ37468817-79972509-50CF-4D3A-AF99-62494E5F1B57Q37956401-91A31E0C-FCC4-4931-B34F-7560E1E746DCQ37965640-5BE41308-92D2-48EF-B588-F279FCAD9FDCQ38127715-AFF5B51A-C9C9-4390-95E4-E79A55D117F3Q38387640-8E3B9C41-12D8-4B99-A5B2-54F5DB68245EQ38740840-64AE3473-9613-4A64-91FC-79C271D38176Q39196970-D705F762-CB41-490B-9329-BFD097BD5A23Q40768545-B83E29CF-B389-48B4-8D96-4BCB32FE35F7Q41008491-BA697085-AD41-4AB3-AA04-492BFFB8D8D6Q41485116-56867D0E-58BA-48A2-8ADC-87C50E6745AC
P2860
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A randomised comparison betwee ...... reatment in colorectal cancer.
@en
A randomised comparison betwee ...... reatment in colorectal cancer.
@nl
type
label
A randomised comparison betwee ...... reatment in colorectal cancer.
@en
A randomised comparison betwee ...... reatment in colorectal cancer.
@nl
prefLabel
A randomised comparison betwee ...... reatment in colorectal cancer.
@en
A randomised comparison betwee ...... reatment in colorectal cancer.
@nl
P2093
P356
P1433
P1476
A randomised comparison betwee ...... reatment in colorectal cancer.
@en
P2093
A R Norman
P304
P356
10.1093/ANNONC/MDI116
P577
2005-02-02T00:00:00Z